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FURIN REDUCES CARTILAGE DEGRADATION IN A MURIN MODEL OF
JOINT INSTABILITY
H. Lin 1, E. Hay 1, W. Bouaziz 1, T. Funck Brentano 1, A.M. Khatib 2,
M.E. Cohen-solal 1. 1 Inserm U606, Paris, France; 2 Inserm U1029, Bordeaux,
France
Aim of the study: Cartilage degradation in OA is mainly due to a reduced
matrix protein secretion and an increase of their degradation by matrix
metalloprotease (MMP). Indeed during OA an enhanced expression and
activation of MMPs is observed. The major MMPs involve in matrix
protein degradation are ADAMTS-4, MMP-3 or MMP-13. However, inhi-
bition of expression or activation of MMPs might reduce matrix degra-
dation during OA. Furin, a proprotein convertase, is responsible for the
conversion of various Pro-MMPs in active MMPs. Furin activates directly
ADAMTS-4 and MMP-3, while promote indirectly the maturation of
MMP-13 through other MMPs. Therefore, we hypothesised that Furin
may have an impact in matrix homeostasis in joint instability. Moreover,
we investigated the in vitro effect of Furin in MMP expression in murin
chondrocytes.
Methods: DMM (destabilisation medial meniscus) was induced surgically
by partial meniscectomy in 10-week-old C57Bl6 male mice. The day after
surgery, the mice received twice weekly intraperitoneal injections of Furin
(1U/mouse), or a1-PDX (the proprotein convertase inhibitor, 0.35 mg/g
mice), or vehicle (control group) and sacriﬁced after 6 weeks. Joint sections
were used to assess cartilage damage (OARSI score) and the number of
ADAMTS-4 and MMP-13(+) cells as well as Furin expressing cells. We
further assessed the signalling pathway induced by Furin in vitro. Murine
primary chondrocytes (pre-treated with 10ng/ml IL-1) were cultured with
Furin (10U/mL) or a1-PDX (8mM) for 48h and then analyzed the expression
of MMP-13 and the phosphorylation of Smad2/3 in cell lysates by Western
blot.
Results:We ﬁrst observed a constitutive expression of Furin in cartilage of
control mice while absent in DMM mice. Furin reduces OA score
(5.641.54) but unchangedwith a1-PDX (15.162.82) compared to vehicle
(13.921.95, p<0.02). The percentage of ADAMTS-4(+) cells was unaf-
fected by Furin or a1-PDX. However, the percentage of MMP-13(+) cells
was signiﬁcantly reduced with Furin (-76%, p<0.03) and unaffected by a1-
PDX. In vitro, Western blot analysis revealed the presence of the active
form of MMP-13 only in IL-1-activated chondrocytes compared to control
suggesting a complete maturation of MMP-13. In contrast, Furin-treated
cells showed a decrease in MMP-13 expression and maturation whereas
a1-PDX had no effect on activated chondrocytes. Moreover, Furin
enhanced the phosphorylation of SMAD2/3 suggesting the activation of
TGFb pathway.
Conclusion: In mice, Furin reduced cartilage degradation induced by DMM
as well as MMP-13 expression. Moreover, Furin decreased the in vitro
maturation of MMP-13 which might be mediated by another signalling
pathway.
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EFFICACY OF THE SELECTIVE INDUCIBLE NITRIC OXIDE SYNTHASE
INHIBITOR SD-6010 IN NONCLINICAL INFLAMMATORY, NEUROPATHIC,
AND OSTEOARTHRITIS PAIN
J.R. Connor 1, K. Rogers 2, T. Sunyer 3, M.-P. Hellio Le Graverand-
Gastineau 4, P.T. Manning 5. 1Medimmune LLC, Gaithersburg, MD, USA;
2Comentis Inc., Oklahoma City, OK, USA; 3Covidien Pharmaceuticals,
Webster Groves, MO, USA; 4 Pﬁzer Inc., Groton, CT, USA; 5Vasculox Inc., St
Louis, MO, USA
Purpose: To evaluate efﬁcacy of SD-6010, a selective inducible nitric oxide
synthase (iNOS) inhibitor, in four pain models.
Methods: Efﬁcacy of oral SD-6010 was evaluated in acute inﬂammatory
hyperalgesia (carrageenan-induced thermal hyperalgesia [CITH]);
peripheral neuropathic pain (spinal nerve ligation [SNL] and chronic
constriction injury [CCI]); and osteoarthritis (OA) pain (medial meniscal
tear [MMT]) in male Sprague-Dawley rats. In the CITH study, efﬁcacy of
oral SD-6010 (50 mg/kg or 150 mg/kg), the selective iNOS inhibitor N-iminoethyl-L-lysine (L-NIL; 30 mg/kg; positive control), or vehicle (nega-
tive control; n ¼ 6 per treatment) administered 4h after carrageenan
injection was determined by measuring paw withdrawal response to
a thermal stimulus at 1, 2, or 3 h thereafter. In studies that utilized the
other models, tactile hypersensitivity of the hindpaws was assessed by
measuring paw withdrawal threshold in response to probing with a series
of calibrated von Frey ﬁlaments applied perpendicularly to the plantar
aspect of the affected paw following oral administration of SD-6010 (SNL:
3,10, 30, or 100mg/kg, n¼6 per treatment; CCI: 3, 10, or 30 mg/kg, n¼6 per
treatment; MMT: 15, 50, or 150 mg/kg, n¼8 per treatment), gabapentin
(SNL: 3, 10, 30 or 100 mg/kg; CCI: 30 mg/kg), or vehicle (SNL only). Efﬁcacy
of SD-6010 in relieving OA-like pain in the MMT model was evaluated as
the weight bearing differential.
Results: A single dose of SD-6010 reduced acute inﬂammatory pain
(thermal hyperalgesia) in a dose-dependent manner (Figure 1). In both
models of neuropathic pain, SD-6010 produced dose-and time-depen-
dent inhibition of pain. In the SNL model, doses of SD-6010 from 10 mg/
kg to 100 mg/kg provided maximal efﬁcacy at 6 hours after adminis-
tration, comparable to gabapentin 30 mg/kg (Figure 2). Peak efﬁcacy
with both SD-6010 and gabapentin occurred between 4 and 6 hours
after administration. In the CCI model, efﬁcacy of 30 mg/kg of SD-6010
was comparable to 30 mg/kg gabapentin (Figure 3). Maximal efﬁcacy
with SD-6010 treatment occurred later than with gabapentin, but SD-
6010 duration of efﬁcacy was considerably longer in CCI. In the MMT
model of OA pain, SD-6010 also reduced tactile hypersensitivity at
doses of 50 mg/kg and 150 mg/kg and weight bearing at all doses
(Figure 4).
Conclusions: The selective iNOS inhibitor SD-6010 reduces pain in rodent
models of inﬂammatory, neuropathic, and osteoarthritis pain.Ă
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CHONDROPROTECTIVE EFFECT OF ALENDRONATE IN A RABBIT MODEL
OF OSTEOARTHRITIS
T. Shirai 1, M. Kobayashi 1, K. Nishitani 1, T. Satake 1, H. Kuroki 1,
Y. Nakagawa 2, C. Tanaka 3, T. Nakamura 1. 1Kyoto Univ., Kyoto, JAPAN;
2Kyoto Med. Ctr., Kyoto, JAPAN; 3Kyoto City Hosp., Kyoto, JAPAN
Purpose: It is generally recognized that osteoarthritis (OA) is a complex
multifactorial disease process involving articular cartilage, subchondral
bone, tendons, and synovium. Alendronate (ALN) inhibits bone loss and
increases bone mineralization. The aim of this study was to examine
whether ALN altered cartilage degeneration and periarticular bone quality
in the rabbit anterior cruciate ligament transection (ACLT) model of OA.
Moreover, the mechanism responsible for ALN effects on cartilage was
investigated using immunohistochemical analysis.
Methods: Skeletally matured, thirty female Japanese white rabbits
underwent an ACLT on the left knee and a sham operation on the right
knee. Fifteen rabbits then received weekly subcutaneous injections of ALN
(0.14 mg/kg) beginning on the day of surgery and 15 rabbits received
subcutaneous injections of saline according to the same schedule. Five
animals from each group were sacriﬁced 2, 4 or 12 weeks after surgery.
Sixty operated knees of 30 rabbits were divided into four groups. The right
and left knees of rabbits that received saline treatment (control [cont]
group) and those of rabbits that received ALN treatment were designated
cont/sham, cont/ACLT, ALN/sham and ALN/ACLT, respectively. Assays for
serum N-telopeptide of type I collagen (NTX) level were performed before
treatment of ALN and after sacriﬁced. The distal femur and the proximal
tibia were scanned by micro-computed tomography (mCT) to quantify the
bone volume ratio. Macroscopic view, histological score, tartrate-resistant
acid phosphatase (TRAP) staining and immunohistochemical index for
matrix metalloproteinase 13 (MMP13), interleukin-1b (IL-1b), type Xcollagen (COLX), vascular endothelial growth factor (VEGF), receptor
activator of nuclear factor kB ligand (RANKL) were evaluated for each
group.
Results: Serum NTX level was suppressed by ALN at 4 weeks post-surgery.
Twelve weeks after the surgery, the cont/ACLT group had more peri-
articular trabecular bone loss and osteophyte formation than the cont/
sham group. However, the ALN/ACLT group maintained bone formation in
a manner similar to that of the ALN/sham group. The expression of TRAP-
positive osteoclasts in subchondral bone was prevented by ALN. Macro-
scopic and histological evaluation revealed that the cont/ACLT group had
signiﬁcantly worse cartilage damage than the cont/sham group 12 weeks
after the surgery, but the ALN/ACLT group had mild cartilage degeneration
compared with that of the ALN/sham group. Protein expression levels of
MMP13, IL-1b, COLX, VEGF and RANKL in the cartilage were suppressed in
the ALN/ACLT group compared with the cont/ACLT group.
Conclusions: The effect of ALN as a potent inhibitor of osteoclastic bone
resorption was veriﬁed by suppressed serum NTX level, increased sub-
chondral bone volume and inhibited TRAP-positive osteoclasts expres-
sion. Macroscopically and histologically, ALN had a chondroprotective
effect in our experimental rabbit model of OA. Immunohistochemical
analysis showed that ALN suppressed the expression of MMP13, IL-1b,
COLX, VEGF and RANKL in OA cartilage. We propose that ALN protects
normal joint loading by preserving subchondral bone quality and
thereby conserves articular cartilage by inhibiting the expression of
MMP13, IL-1b, COLX, VEGF and RANKL. Our results suggest therapeutic
roles for ALN in inhibiting subchondral bone loss in the early stage of OA,
in protecting cartilage against degeneration and in preserving long-term
joint function.
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RANKL PRODUCED BY ARTICULAR CHONDROCYTES INDUCES BONE
LOSS ASSOCIATED WITH ARTHROPATHIES
I. Prieto-Potin, M.J. Martínez-Calatrava, J.A. Román-Blas, R. Largo,
L. Tardío, G. Herrero-Beaumont. Bone and Joint Res. Unit, Dept. of
Rheumatology, IIS-Fundación Jiménez Díaz, Univ. Autónoma, Madrid, Spain
Purpose: Juxta-articular bone loss is a radiographic lesion associated with
rheumatoid arthritis (RA) and early osteoarthritis (OA). Its molecular
mechanisms are not yet completely elucidated. Even though we demon-
strated that RANKL diffuses from the cartilage to the subchondral bone
(Moreno-Rubio et al, 2010), its role in the juxta-articular bone loss remains
still unclear. This study was designed to determine whether RANKL
produced by chondrocytes is able to induce juxta-articular bone loss
related to RA and early OA.
Methods: Chronic antigen-induced arthritis (AIA) was induced in 7 New
Zealand male previously immunized rabbits of 3 - 3,5 kg by 4 weekly
repeated intra-articular injections of ovalbumin (OVA). Animals were
euthanized 4 weeks after the end of OVA injections. Surgical OA was
induced in the knees of 3 sex and weight-matched animals by partial
medial menistectomy and transection of the anterior cruciate ligament.
Rabbits were euthanized after 8 weeks of evolution. A control group of 8
weight and sex-matched animals was simultaneously studied. Dual energy
X-ray absorptiometry of subchondral knee bone was performed before
sacriﬁce. Articular cartilage, synovium and subchondral bone of the tibia
were isolated and frozen for OPG and RANKL expression studies, while
femurs were ﬁxed, decalciﬁed and embedded in parafﬁn for histological
examination and RANKL immunohistochemistry assessment. Osteoclast in
vitro differentiation induced by chondrocytes was studied in co-culture of
human chondrocytes with peripheral blood mononuclear cells, in pres-
ence of M-CSF and PG-E2, and further stained with tartrate-resistant acid
phosphatase.
Results: AIA rabbits showed bone mineral density (BMD) values of knee
subchondral bone signiﬁcantly lower than healthy ones (0.270.04 vs
0.550.05 gr/cm2; p¼0.029). Therewas no difference between BMD values
of AIA and OA rabbits. Nonetheless, a decreased tendency of OA rabbits
BMD was evidenced in subchondral bone compared with controls
(0.430.06 vs 0.550.05 gr/cm2, p¼0.057). The expression of RANKL
(876.8149.52 vs 64.1522.26 AU; p<0.001), OPG (153.7954.63 vs
35.6318.22 AU; p<0.001) and the RANKL/OPG ratio (6.202.13 vs
3.850.90, p¼0.009) were signiﬁcantly higher in AIA rabbits than in
